false
OasisLMS
Catalog
WCLC 2025 - Posters & ePosters
EP.06.26 Resectable Lung Cancer With KRAS Mutation ...
EP.06.26 Resectable Lung Cancer With KRAS Mutation May Have Less Lymphatic Metastasis
Back to course
Pdf Summary
This study from Tohoku University analyzed 291 cases of resectable early-stage lung cancer between January 2022 and July 2024, focusing on driver gene mutations and their association with pathological features. Using multigene PCR panel testing, the researchers identified mutations in EGFR (37%), KRAS (14%), and other genes such as BRAF, HER2, RET, and MET, with 40% of tumors negative for known driver mutations.<br /><br />Key findings centered on KRAS-mutated non-small cell lung cancer (NSCLC). Patients with KRAS mutations showed significantly less lymph node metastasis (N1/N2: 5%) compared to KRAS-negative cases (16%, p=0.038). Similarly, lymphatic invasion was less frequent in KRAS mutants (8% vs 17%), though this was not statistically significant. Conversely, KRAS-mutated tumors had a higher tendency for pleural invasion, suggesting that tumor spread for these cases may occur more via pleural dissemination rather than lymphatic pathways.<br /><br />These findings contrast with some previous reports and highlight the heterogeneity of KRAS-mutated lung cancers. The study concludes that KRAS mutations in early-stage NSCLC are associated with less lymphatic metastasis but more pleural invasion, which could influence disease prognosis and patterns of tumor dissemination.<br /><br />Overall, the research suggests the invasion mechanism of KRAS-mutated lung cancers differs from other driver mutations like EGFR, emphasizing the importance of genetic profiling even in early resectable lung cancers to better understand their pathological behavior and potential therapeutic implications.
Asset Subtitle
Chikara Nakagami
Meta Tag
Speaker
Chikara Nakagami
Topic
Pathology and Biomarkers
Keywords
Tohoku University
early-stage lung cancer
driver gene mutations
EGFR mutation
KRAS mutation
non-small cell lung cancer
lymph node metastasis
pleural invasion
multigene PCR panel
tumor dissemination
×
Please select your language
1
English